Literature DB >> 25339042

Prognostic values of VEGF and endostatin with malignant pleural effusions in patients with lung cancer.

Yu Zhang1, Li-Ke Yu, Guo-Jun Lu, Ning Xia, Hai-Yan Xie, Wei Hu, Ke-Ke Hao, Chun-Hua Xu, Qian Qian.   

Abstract

AIMS: Angiogenesis is important in malignant pleural effusion (MPE) formation and it is regulated by a number of pro- and anti-angiogenic cytokines. The purpose of this study was to evaluate the prognostic value of angiogenic factor vascular endothelial growth factor (VEGF) and angiogenesis inhibitor endostatin in lung cancer patients with MPE, and investigate the relationship between these two kinds of agent.
METHODS: Using enzyme-linked immunoadsorbent assay, the concentrations of VEGF and endostatin were measured in pleural effusions (PE) and serum from a total of 70 lung cancer patients with MPE and 20 patients with tuberculosis.
RESULTS: Compared to patients with tuberculosis, the levels of VEGF and endostatin in both PE and serum were significantly higher in patients with lung cancer. There were statistically significant correlations between VEGF levels in PE and serum (r=0.696, <0.001), endostatin levels in PE and serum (r=0.310, p=0.022), and VEGF and endostatin levels in PE (r=0.287, p=0.019). Cox multivariate analysis revealed that elevated pleural VEGF and endostatin levels and serum endostatin level were independent predictors of shorter overall survival.
CONCLUSION: Both pro- and anti-angiogenic factors are likely contributors to PE formation. Our results suggest that the levels of VEGF and endostatin in PE, together with endostatin in serum, may be potential prognostic parameters for lung cancer patients with MPE.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25339042     DOI: 10.7314/apjcp.2014.15.19.8435

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  9 in total

Review 1.  Closing faucets: the role of anti-angiogenic therapies in malignant pleural diseases.

Authors:  D Marquez-Medina; S Popat
Journal:  Clin Transl Oncol       Date:  2015-12-17       Impact factor: 3.405

2.  Effect of Endostar combined with angiopoietin-2 inhibitor on malignant pleural effusion in mice.

Authors:  Shen-Cun Fang; Hai-Tao Zhang; Hui-Di Hu; Cai-Ying Wang; Ying-Ming Zhang
Journal:  Med Oncol       Date:  2014-12-06       Impact factor: 3.064

3.  Vascular endothelial growth factor levels in tuberculosis: A systematic review and meta-analysis.

Authors:  Amene Saghazadeh; Nima Rezaei
Journal:  PLoS One       Date:  2022-05-25       Impact factor: 3.752

4.  Predictive significance of combined LAPTM4B and VEGF expression in patients with cervical cancer.

Authors:  Fanling Meng; Shu Tan; Tianbo Liu; Hongtao Song; Ge Lou
Journal:  Tumour Biol       Date:  2015-11-02

5.  Effects of Copper Reduction on Angiogenesis-Related Factorszzm321990in Recurrent Glioblastoma Cases

Authors:  Shima Jazayeri; Alireza Feli; Mohammad Ali Bitaraf; Masoud Solaymani Dodaran; Mazdak Alikhani; Mohammad Javad Hosseinzadeh-Attar
Journal:  Asian Pac J Cancer Prev       Date:  2016-10-01

6.  Differential effects of recombinant human endostatin treatment on differentiated and undifferentiated blood vessels in Lewis lung cancer.

Authors:  Weijiang Fu; Jing Zhuo; Likuan Hu
Journal:  Oncol Lett       Date:  2016-11-30       Impact factor: 2.967

7.  Identification of differentially expressed miRNAs in differentiating benign from malignant pleural effusion.

Authors:  Quanlei Bao; Yaping Xu; Ming Ding; Ping Chen
Journal:  Hereditas       Date:  2020-02-26       Impact factor: 3.271

8.  Development of RECLS score to predict survival in lung cancer patients with malignant pleural effusion.

Authors:  Tianli Zhang; Xi Chen; Bing Wan; Yangyang Xu; Hongbing Liu; Tangfeng Lv; Ping Zhan; Yong Song
Journal:  Transl Lung Cancer Res       Date:  2021-03

Review 9.  The role of VEGF in the diagnosis and treatment of malignant pleural effusion in patients with non‑small cell lung cancer (Review).

Authors:  Yao Chen; Nicholas W Mathy; Hongda Lu
Journal:  Mol Med Rep       Date:  2018-04-23       Impact factor: 2.952

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.